Sunovion seeks US FDA's OK for Latuda in bipolar disorder
This article was originally published in Scrip
Executive Summary
Sunovion Pharmaceuticals is seeking the US FDA's nod for broader use of the firm’s atypical antipsychotic Latuda (lurasidone HCl) as a monotherapy to treat adults with depressive episodes associated with bipolar I disorder, and as an adjunctive therapy to lithium or valproate for the same indication.